BIOMAT Database Logo BIOMAT Database Logo

Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. 1997

J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA.

BACKGROUND Inhibitory antibodies which neutralise factor VIII develop in 10-20% of individuals with inherited haemophilia A and rarely as autoantibodies in normal individuals to cause acquired haemophilia. The antibodies are directed against human factor VIII but cross-react to varying degrees with porcine factor VIII. Porcine factor VIII can be used for treatment in individuals with low cross-reactivity. OBJECTIVE To determine the cross-reactivity of factor VIII inhibitors between human factor VIII and porcine factor VIII, in a population of patients with inherited and acquired haemophilia A. Also, to determine whether patients with inherited haemophilia and inhibitors have a higher incidence of factor VIII gene inversion in intron 22. METHODS Samples and data sheets from 43 patients with inherited and ten with acquired haemophilia were submitted from hospitals in Australia and New Zealand. Inhibitor levels to human and porcine factor VIII were measured by the Bethesda method in 39 with inherited and nine with acquired haemophilia A. RESULTS Of 39 patients with inherited haemophilia A, cross-reactivity was 0% in 17 patients, 1-19% in six, 20-39% in 11 and 40-80% in five. In six of nine patients with acquired haemophilia cross-reactivity was < or = 7%. In inherited severe haemophilia A, the frequency of the intron 22 inversion was not greater in 37 study patients than in 28 patients without an inhibitor. CONCLUSIONS Many patients in Australia and New Zealand with inhibitors to human factor VIII presently show a low or absent level of cross-reactivity to porcine factor VIII. These may respond to treatment with this concentrate at least in the short term. There remains a group of patients with high cross-reactivity who will respond only to recombinant factor VIIa or prothrombin complex concentrates.

UI MeSH Term Description Entries
D007446 Chromosome Inversion An aberration in which a chromosomal segment is deleted and reinserted in the same place but turned 180 degrees from its original orientation, so that the gene sequence for the segment is reversed with respect to that of the rest of the chromosome. Inversion, Chromosome,Inversion, Chromosomal,Chromosomal Inversion,Chromosomal Inversions,Chromosome Inversions,Inversions, Chromosomal,Inversions, Chromosome
D009520 New Zealand A group of islands in the southwest Pacific. Its capital is Wellington. It was discovered by the Dutch explorer Abel Tasman in 1642 and circumnavigated by Cook in 1769. Colonized in 1840 by the New Zealand Company, it became a British crown colony in 1840 until 1907 when colonial status was terminated. New Zealand is a partly anglicized form of the original Dutch name Nieuw Zeeland, new sea land, possibly with reference to the Dutch province of Zeeland. (From Webster's New Geographical Dictionary, 1988, p842 & Room, Brewer's Dictionary of Names, 1992, p378)
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001315 Australia The smallest continent and an independent country, comprising six states and two territories. Its capital is Canberra. Canton and Enderbury Islands,Christmas Island,Christmas Island (Australia)
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog

Related Publications

J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.
September 1995, Blood,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Highly purified porcine factor VIII in haemophilia A with inhibitors to factor VIII.
January 1981, British medical journal (Clinical research ed.),
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Porcine factor VIII therapy in patients with factor VIII inhibitors.
January 1995, Advances in experimental medicine and biology,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.
May 2002, Haemophilia : the official journal of the World Federation of Hemophilia,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Factor VIII inhibitors in haemophilia.
April 1983, Lancet (London, England),
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII.
September 2000, Haemophilia : the official journal of the World Federation of Hemophilia,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Anti-factor-VIII inhibitors in haemophilia.
August 1989, Lancet (London, England),
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
The economic impact of factor VIII inhibitors in patients with haemophilia.
January 2004, Haemophilia : the official journal of the World Federation of Hemophilia,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.
April 2017, Journal of clinical medicine,
J V Lloyd, and A M Street, and E Berry, and J McPherson, and H Ekert, and A Lammi, and W R McWhirter, and E M Duncan, and E L Maxwell, and J Rowell, and R I Baker, and M F Leahy, and D Jupe
Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
July 2020, Haemophilia : the official journal of the World Federation of Hemophilia,
Copied contents to your clipboard!